Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 24, 2021
- Accepted in final form July 6, 2021
- First Published August 9, 2021.
Author Disclosures
- Luca Prosperini, MD, PhD,
- Serena Ruggieri, MD, PhD (serena.ruggieri{at}gmail.com),
- Shalom Haggiag, MD (lvshalom{at}hotmail.com),
- Carla Tortorella, MD (carla.tortorella{at}gmail.com),
- Carlo Pozzilli, MD, PhD (carlo.pozzilli{at}uniroma1.it) and
- Claudio Gasperini, MD, PhD (c.gasperini{at}libero.it)
- Luca Prosperini, MD, PhD,
(1) Biogen (2) Celgene-BMS (3) Novartis (4) Sanofi Genzyme
NONE
(1) Almirall (2) Biogen (3) Genzyme (4) Merck Serono (5) Novartis (6) Roche (7) Teva
(1) BMC Neurology, associate editor, 2014 (2) BioMed Research International, associate editor, 2015
NONE
NONE
NONE
(1) Biogen (2) Novartis (3) Genzyme
NONE
NONE
NONE
(1) Genzyme, research grant
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Serena Ruggieri, MD, PhD (serena.ruggieri{at}gmail.com),
(1) Merck Serono (2) Novartis (3) Biogen
NONE
(1) Merck Serono: speaker honoraria (2) Biogen: speaker honoraria (3) Merck Serono: Funding for travel (4) Biogen: Funding for travel
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shalom Haggiag, MD (lvshalom{at}hotmail.com),
NONE
NONE
travel funding and/or speaker honoraria from Roche, Genzyme, Novartis and CSL Behring
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Carla Tortorella, MD (carla.tortorella{at}gmail.com),
Advisory board for Merck Serono, Teva, Genzyme, Biogen, Roche, Novartis
NONE
received honoraria for travel or speaking from Biogen, Sanofi-Aventis, Serono and Bayer-Schering, Teva, Genzyme, Roche and Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Carlo Pozzilli, MD, PhD (carlo.pozzilli{at}uniroma1.it) and
Novartis, Merck Serono, Biogen, Sanofi-Aventis, Roche, Actelion
NONE
Novartis, Merck Serono, Biogen,Sanofi Aventis, Roche.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claudio Gasperini, MD, PhD (c.gasperini{at}libero.it)
(1) Merck (2) Genzyme (3) Teva (4) Biogen (5) Roche (6) Almirall
NONE
Speaker honoraria for (1)Merck: speaker honoraria/ travel (2)Genzyme: speaker honoraria / travel (3)Biogen: speaker honoraria / travel (4)Teva: speaker honoraria / travel (5) Roche: speaker honoraria/travel (6)Novartis: travel
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurosciences (L.P., S.H., C.T., C.G.), S. Camillo-Forlanini Hospital; Department of Human Neurosciences (S.R., C.P.), Sapienza University; and Neuroimmunology Unit (S.R.), Santa Lucia Foundation, Rome, Italy.
- Correspondence
Dr. Prosperini luca.prosperini{at}gmail.com
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Comparative effectiveness of teriflunomide and dimethyl fumarateA nationwide cohort studyMathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg et al.Neurology, March 15, 2019 -
Article
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSJohannes Lorscheider, Vilija G. Jokubaitis, Tim Spelman et al.Neurology, August 09, 2017 -
Article
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosisFrederik Barkhof, Ludwig Kappos, Jerry S. Wolinsky et al.Neurology, September 04, 2019 -
Research Article
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple SclerosisA Real-world Case SeriesRichard S. Nicholas, Elijah E. Rhone, Alice Mariottini et al.Neurology, July 12, 2021